
## Martina Garau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2759877/publications.pdf Version: 2024-02-01



MADTINA CADALI

#	Article	IF	CITATIONS
1	Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB. BMJ Global Health, 2020, 5, e002061.	4.7	2
2	Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. Value in Health, 2019, 22, 1283-1288.	0.3	97
3	Comparing access to orphan medicinal products in Europe. Orphanet Journal of Rare Diseases, 2019, 14, 95.	2.7	57
4	Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). PharmacoEconomics - Open, 2018, 2, 153-163.	1.8	22
5	Using MCDA as a Decision Aid in Health Technology Appraisal for Coverage Decisions: Opportunities, Challenges and Unresolved Questions. , 2017, , 277-298.		4
6	IS THE LINK BETWEEN HEALTH AND WEALTH CONSIDERED IN DECISION MAKING? RESULTS FROM A QUALITATIVE STUDY. International Journal of Technology Assessment in Health Care, 2015, 31, 449-456.	0.5	4
7	PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH. International Journal of Technology Assessment in Health Care, 2015, 31, 90-98.	0.5	16
8	The future of comparative effectiveness and relative efficacy of drugs: an international perspective. Journal of Comparative Effectiveness Research, 2015, 4, 419-427.	1.4	8
9	Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020. Journal of Comparative Effectiveness Research, 2015, 4, 401-418.	1.4	5
10	Can and should value-based pricing be applied to molecular diagnostics?. Personalized Medicine, 2013, 10, 61-72.	1.5	30
11	Using QALYs in Cancer. Pharmacoeconomics, 2011, 29, 673-685.	3.3	74